Advertisement

Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type

  • Shiho AsakaEmail author
  • Tomoyuki Nakajima
  • Kaori Kugo
  • Risako Kashiwagi
  • Nozomi Yazaki
  • Tsutomu Miyamoto
  • Takeshi Uehara
  • Hiroyoshi Ota
Original Article
Part of the following topical collections:
  1. Quality in Pathology

Abstract

A classification system for invasive endocervical adenocarcinoma (ECA) focusing on high-risk human papillomavirus (HPV) detection has been recently developed. However, precursor lesions of each ECA subtype and immunohistochemical markers that effectively subcategorize ECAs with gastric and intestinal differentiation have not been fully described. Here, we aimed to subcategorize endocervical adenocarcinoma in situ (AIS) by immunophenotype and to characterize the histopathology of each AIS subtype. We immunohistochemically analyzed 36 AIS and 25 lobular endocervical glandular hyperplasia (LEGH) samples using three cell lineage–specific markers (CLDN18, gastric epithelial cells; CDH17, intestinal epithelial cells; and PAX8, Müllerian epithelial cells). The AISs were immunophenotypically classified as gastric-type (G-AIS; n = 2), intestinal-type (I-AIS; n = 10), gastrointestinal-type (GI-AIS; n = 3), Müllerian-type (M-AIS; n = 18), and AIS, not otherwise specified (AIS-NOS; n = 3). All 25 LEGHs were categorized as gastric-type. G-AIS had pale eosinophilic or clear cytoplasm with a small amount of apical mucin and fewer mitotic bodies. I-AIS comprised various numbers of goblet cell-type tumor cells. GI-AIS showed intermediate or mixed features of G-AIS and I-AIS. M-AIS, as with the usual-type ECA, was typically characterized by mucin depletion; however, several lesions had abundant cytoplasmic mucin. High-risk HPV was detected in most AISs but was negative in 100% (2/2) of G-AIS, 10% (1/10) of I-AIS, and 6% (1/18) of M-AIS lesions. In summary, the AIS subtypes defined by immunophenotype had distinct histopathological and etiological characteristics. Thus, immunophenotyping with CLDN18, CDH17, and PAX8 might improve the diagnostic accuracy of histopathological classifications of ECAs.

Keywords

Endocervical adenocarcinoma in situ Immunohistochemistry Gastric type Intestinal type Lobular endocervical glandular hyperplasia Human papillomavirus 

Notes

Acknowledgments

We thank Kayo Suzuki and Misako Yamada (Research Center for Supports to Advanced Science, Shinshu University) and Chinatsu Kobayashi and Masayuki Ito (Department of Clinical Laboratory Sciences, Shinshu University School of Medicine) for providing expert technical assistance. We also thank Editage (www.editage.jp) for English language editing.

Contributions

Conceptualization: Shiho Asaka and Hiroyoshi Ota; Methodology: Shiho Asaka, Tomoyuki Nakajima, Takeshi Uehara, and Hiroyoshi Ota; Formal analysis and investigation: Shiho Asaka, Tomoyuki Nakajima, Kaori Kugo, Risako Kashiwagi, Nozomi Yazaki, and Hiroyoshi Ota; Writing—original draft preparation: Shiho Asaka; Writing—review and editing: Hiroyoshi Ota; Funding acquisition: Shiho Asaka and Hiroyoshi Ota; Resources: Tsutomu Miyamoto and Takeshi Uehara; Supervision: Hiroyoshi Ota. All authors gave final approval for publication. Shiho Asaka takes full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript.

Funding information

This work was funded by the Japan Society for the Promotion of Science (JSPS), Grants-in-Aid for Scientific Research (KAKENHI) to Shiho Asaka (17K15641) and Hiroyoshi Ota (17K09010).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

428_2019_2739_MOESM1_ESM.pdf (1.5 mb)
ESM 1 (PDF 1495 kb)

References

  1. 1.
    Smith HO, Tiffany MF, Qualls CR, Key CR (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol 78(2):97–105.  https://doi.org/10.1006/gyno.2000.5826 CrossRefGoogle Scholar
  2. 2.
    Adegoke O, Kulasingam S, Virnig B (2012) Cervical cancer trends in the United States: a 35-year population-based analysis. J Women's Health 21(10):1031–1037.  https://doi.org/10.1089/jwh.2011.3385 CrossRefGoogle Scholar
  3. 3.
    Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev 14(9):2191–2199.  https://doi.org/10.1158/1055-9965.Epi-05-0231 CrossRefGoogle Scholar
  4. 4.
    Pirog EC, Lloveras B, Molijn A, Tous S, Guimera N, Alejo M, Clavero O, Klaustermeier J, Jenkins D, Quint WG, Xavier Bosch F, Alemany L, de Sanjose S (2014) HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol 27(12):1559–1567.  https://doi.org/10.1038/modpathol.2014.55 CrossRefGoogle Scholar
  5. 5.
    Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98(5):303–315.  https://doi.org/10.1093/jnci/djj067 CrossRefGoogle Scholar
  6. 6.
    Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, Soslow RA, Park KJ (2015) Gastric-type endocervical adenocarcinoma an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol 39(11):1449–1457.  https://doi.org/10.1097/pas.0000000000000532 CrossRefGoogle Scholar
  7. 7.
    Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, Nishimura R (2010) Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol 177(5):2169–2175.  https://doi.org/10.2353/ajpath.2010.100323 CrossRefGoogle Scholar
  8. 8.
    Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R (2007) Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol 31(5):664–672.  https://doi.org/10.1097/01.pas.0000213434.91868.b0 CrossRefGoogle Scholar
  9. 9.
    Mikami Y, Kyokawa T, Hata S, Fujiwara K, Moriya T, Sasano H, Manabe T, Akahira JI, Ito K, Tase T, Yaegashi N, Sato I, Tateno H, Naganuma H (2004) Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and ‘adenoma malignum’. Mod Pathol 17(8):962–972.  https://doi.org/10.1038/modpathol.3800148 CrossRefGoogle Scholar
  10. 10.
    Nucci MR, Clement PB, Young RH (1999) Lobular endocervical glandular hyperplasia, not otherwise specified: a clinicopathologic analysis of thirteen cases of a distinctive pseudoneoplastic lesion and comparison with fourteen cases of adenoma malignum. Am J Surg Pathol 23(8):886–891CrossRefGoogle Scholar
  11. 11.
    Kawauchi S, Kusuda T, Liu XP, Suehiro Y, Kaku T, Mikami Y, Takeshita M, Nakao M, Chochi Y, Sasaki K (2008) Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma? A comparative molecular-genetic and immunohistochemical study. Am J Surg Pathol 32(12):1807–1815.  https://doi.org/10.1097/PAS.0b013e3181883722 CrossRefGoogle Scholar
  12. 12.
    Wilbur DC, Mikami Y, Colgan TJ, Park KJ, Ferenczy AS, Ronnett BM, Hirschowitz L, Schneider A, Loening T, Soslow R, McCluggage WG, Wells M, Wright T (2014) Glandular tumours and precursors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) WHO classification of tumours of female reproductive organs, 4th edn. International Agency for Research on Cancer, Lyon, pp 183–189Google Scholar
  13. 13.
    Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA (2018) International endocervical adenocarcinoma criteria and classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol 42(2):214–226.  https://doi.org/10.1097/pas.0000000000000986 CrossRefGoogle Scholar
  14. 14.
    Hodgson A, Park KJ, Djordjevic B, B EH, Nucci MR, Oliva E, Stolnicu S, Xu B, Soslow RA, Parra-Herran C (2018) International endocervical adenocarcinoma criteria and classification: validation and interobserver reproducibility. Am J Surg Pathol 43(1):75–83.  https://doi.org/10.1097/pas.0000000000001095 CrossRefGoogle Scholar
  15. 15.
    Stolnicu S, Barsan I, Hoang L, Patel P, Chiriboga L, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA (2018) Diagnostic algorithmic proposal based on comprehensive immunohistochemical evaluation of 297 invasive endocervical adenocarcinomas. Am J Surg Pathol 42(8):989–1000.  https://doi.org/10.1097/pas.0000000000001090 CrossRefGoogle Scholar
  16. 16.
    Stolnicu S, Hoang L, Chiu D, Hanko-Bauer O, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E, Park KJ, Abu-Rustum NR, Soslow RA (2019) Clinical outcomes of HPV-associated and unassociated endocervical adenocarcinomas categorized by the international endocervical adenocarcinoma criteria and classification (IECC). Am J Surg Pathol 43(4):466–474.  https://doi.org/10.1097/pas.0000000000001224 CrossRefGoogle Scholar
  17. 17.
    Hodgson A, Olkhov-Mitsel E, Howitt BE, Nucci MR, Parra-Herran C (2019) International endocervical adenocarcinoma criteria and classification (IECC): correlation with adverse clinicopathological features and patient outcome. J Clin Pathol 72(5):347–353.  https://doi.org/10.1136/jclinpath-2018-205632 CrossRefGoogle Scholar
  18. 18.
    Asaka S, Nakajima T, Momose M, Miyamoto T, Uehara T, Ota H (2019) Trefoil factor family 2 protein: a potential immunohistochemical marker for aiding diagnosis of lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. Virchows Arch 474(1):79–86.  https://doi.org/10.1007/s00428-018-2469-z CrossRefGoogle Scholar
  19. 19.
    Ota H, Hayama M, Nakayama J, Hidaka H, Honda T, Ishii K, Fukushima M, Uehara T, Kurihara M, Ishihara K, Hotta K, Katsuyama T (2001) Cell lineage specificity of newly raised monoclonal antibodies against gastric mucins in normal, metaplastic, and neoplastic human tissues and their application to pathology diagnosis. Am J Clin Pathol 115(1):69–79CrossRefGoogle Scholar
  20. 20.
    Nakajima K, Ota H, Zhang MX, Sano K, Honda T, Ishii K, Nakayama J (2003) Expression of gastric gland mucous cell-type mucin in normal and neoplastic human tissues. J Histochem Cytochem 51(12):1689–1698.  https://doi.org/10.1177/002215540305101213 CrossRefGoogle Scholar
  21. 21.
    Shinozaki A, Ushiku T, Morikawa T, Hino R, Sakatani T, Uozaki H, Fukayama M (2009) Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling. J Histochem Cytochem 57(8):775–785.  https://doi.org/10.1369/jhc.2009.953810 CrossRefGoogle Scholar
  22. 22.
    Tamura A, Yamazaki Y, Hayashi D, Suzuki K, Sentani K, Yasui W, Tsukita S (2012) Claudin-based paracellular proton barrier in the stomach. Ann N Y Acad Sci 1258:108–114.  https://doi.org/10.1111/j.1749-6632.2012.06570.x CrossRefGoogle Scholar
  23. 23.
    Shinozaki A, Shibahara J, Noda N, Tanaka M, Aoki T, Kokudo N, Fukayama M (2011) Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma. Virchows Arch 459(1):73–80.  https://doi.org/10.1007/s00428-011-1092-z CrossRefGoogle Scholar
  24. 24.
    Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, Kokudo N, Fukayama M (2011) Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 59(10):942–952.  https://doi.org/10.1369/0022155411420569 CrossRefGoogle Scholar
  25. 25.
    Halimi SA, Maeda D, Shinozaki-Ushiku A, Koso T, Matsusaka K, Tanaka M, Arimoto T, Oda K, Kawana K, Yano T, Fujii T, Fukayama M (2013) Claudin-18 overexpression in intestinal-type mucinous borderline tumour of the ovary. Histopathology 63(4):534–544.  https://doi.org/10.1111/his.12182
  26. 26.
    Maeda D (2015) Utility of claudin-18 and p16 immunohistochemistry for distinguishing gastric-type adenocarcinoma from other subtypes of cervical adenocarcinoma. Mod Pathol 28:296A–297AGoogle Scholar
  27. 27.
    Ordonez NG (2014) Cadherin 17 is a novel diagnostic marker for adenocarcinomas of the digestive system. Adv Anat Pathol 21(2):131–137.  https://doi.org/10.1097/pap.0000000000000008 CrossRefGoogle Scholar
  28. 28.
    Su MC, Yuan RH, Lin CY, Jeng YM (2008) Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol 21(11):1379–1386.  https://doi.org/10.1038/modpathol.2008.107 CrossRefGoogle Scholar
  29. 29.
    Hinoi T, Lucas PC, Kuick R, Hanash S, Cho KR, Fearon ER (2002) CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology 123(5):1565–1577CrossRefGoogle Scholar
  30. 30.
    Berndorff D, Gessner R, Kreft B, Schnoy N, Lajous-Petter AM, Loch N, Reutter W, Hortsch M, Tauber R (1994) Liver-intestine cadherin: molecular cloning and characterization of a novel Ca(2+)-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol 125(6):1353–1369CrossRefGoogle Scholar
  31. 31.
    Panarelli NC, Yantiss RK, Yeh MM, Liu Y, Chen YT (2012) Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. Am J Clin Pathol 138(2):211–222.  https://doi.org/10.1309/ajcpkshxi3xehw1j CrossRefGoogle Scholar
  32. 32.
    Matsusaka K, Ushiku T, Urabe M, Fukuyo M, Abe H, Ishikawa S, Seto Y, Aburatani H, Hamakubo T, Kaneda A, Fukayama M (2016) Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer. Oncotarget 7(39):64168–64181.  https://doi.org/10.18632/oncotarget.11638
  33. 33.
    Talia KL, Stewart CJ, Howitt BE, Nucci MR, McCluggage WG (2017) HPV-negative gastric type adenocarcinoma in situ of the cervix: a spectrum of rare lesions exhibiting gastric and intestinal differentiation. Am J Surg Pathol 41(8):1023–1033.  https://doi.org/10.1097/pas.0000000000000855 CrossRefGoogle Scholar
  34. 34.
    Park KJ, Kiyokawa T, Soslow RA, Lamb CA, Oliva E, Zivanovic O, Juretzka MM, Pirog EC (2011) Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol 35(5):633–646.  https://doi.org/10.1097/PAS.0b013e31821534b9 CrossRefGoogle Scholar
  35. 35.
    An HJ, Kim KR, Kim IS, Kim DW, Park MH, Park IA, Suh KS, Seo EJ, Sung SH, Sohn JH, Yoon HK, Chang ED, Cho HI, Han JY, Hong SR, Ahn GH (2005) Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol 18(4):528–534.  https://doi.org/10.1038/modpathol.3800316 CrossRefGoogle Scholar
  36. 36.
    Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, Richart RM, Isacson C (2000) Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 157(4):1055–1062.  https://doi.org/10.1016/s0002-9440(10)64619-6 CrossRefGoogle Scholar
  37. 37.
    Carleton C, Hoang L, Sah S, Kiyokawa T, Karamurzin YS, Talia KL, Park KJ, McCluggage WG (2016) A detailed immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas. Am J Surg Pathol 40(5):636–644.  https://doi.org/10.1097/pas.0000000000000578 CrossRefGoogle Scholar
  38. 38.
    Talia KL, Cretney A, McCluggage WG (2014) A case of HPV-negative intestinal-type endocervical adenocarcinoma in situ with coexisting multifocal intestinal and gastric metaplasia. Am J Surg Pathol 38(2):289–291.  https://doi.org/10.1097/pas.0000000000000139 CrossRefGoogle Scholar
  39. 39.
    Kushima R, Hattori T (1993) Histogenesis and characteristics of gastric-type adenocarcinomas in the stomach. J Cancer Res Clin Oncol 120(1–2):103–111CrossRefGoogle Scholar
  40. 40.
    Fujimori Y, Akamatsu T, Ota H, Katsuyama T (1995) Proliferative markers in gastric carcinoma and organoid differentiation. Hum Pathol 26(7):725–734CrossRefGoogle Scholar
  41. 41.
    Kobayashi M, Fujinaga Y, Ota H (2014) Reappraisal of the immunophenotype of pancreatic intraductal papillary mucinous neoplasms (IPMNs)-gastric pyloric and small intestinal immunophenotype expression in gastric and intestinal type IPMNs. Acta Histochem Cytochem 47(2):45–57.  https://doi.org/10.1267/ahc.13027 CrossRefGoogle Scholar
  42. 42.
    Howitt BE, Herfs M, Brister K, Oliva E, Longtine J, Hecht JL, Nucci MR (2013) Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women. Am J Surg Pathol 37(5):625–633.  https://doi.org/10.1097/PAS.0b013e318285be00 CrossRefGoogle Scholar
  43. 43.
    Mikami Y, Hata S, Melamed J, Fujiwara K, Manabe T (2001) Lobular endocervical glandular hyperplasia is a metaplastic process with a pyloric gland phenotype. Histopathology 39(4):364–372.  https://doi.org/10.1046/j.1365-2559.2001.01239.x CrossRefGoogle Scholar
  44. 44.
    Nara M, Hashi A, Murata S-I, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K (2007) Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol 106(2):289–298.  https://doi.org/10.1016/j.ygyno.2007.03.044 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Department of Laboratory MedicineShinshu University School of MedicineMatsumotoJapan
  2. 2.Department of Diagnostic PathologyShinshu University HospitalMatsumotoJapan
  3. 3.Department of Clinical Laboratory SciencesShinshu University School of MedicineMatsumotoJapan
  4. 4.Department of Obstetrics and GynecologyShinshu University School of MedicineMatsumotoJapan

Personalised recommendations